A more discriminate financing environment is emerging in biotech. There is still plenty of private money about: $35 billion of venture capital was raised in 2022, more than during pre-pandemic 2019. But investors aren’t giving it away so easily go.nature.com/3UcPmH0

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy: Cell cell.com/cell/fulltext/…

Delighted that our paper 'Innate receptors with high specificity for HLA class I–peptide complexes' is now published in Science Immunology Science Immunology science.org/doi/10.1126/sc….

It has begun.

Landing tenure is a pipe dream for most postdoctoral researchers. They need business skills to help them thrive outside academia go.nature.com/3slP1Z3

Review Nature Immunology, comparing CAR T and CAR NK cell therapies, focusing on immunological synapses, engineering strategies, and challenges Avery Posey nature.com/articles/s4159…

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies fda.gov/vaccines-blood…

Proud of Matt Bell who published his graduate work on leucine zipper cytokine receptors today in BME! nature.com/articles/s4155…

Full resolution HLA and KIR genes annotation for human genome assemblies biorxiv.org/cgi/content/sh… #biorxiv_immuno

Join us for The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) at St. Jude in June 2024. stjude.org/education-trai… St. Jude St. Jude Research ASTCT The PTCTC

In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy go.nature.com/4cfyac2

Congrats to Jennifer Foltz, PhD Jenn Tran and the whole team! New insights into the molecular program of memory-like #NKcell Test Account WUSTL Immunology Siteman Cancer Center science.org/doi/10.1126/sc…

RNAseq is commonly performed. We compared N=30 wild-type Bl6 mice to an N=30 heterozygotic knockout with a phenotype, and then downsized. We found you need at least an N= 8-12 to avoid a >50% false positive rate. A 2nd line confirmed the finding. biorxiv.org/content/10.110…

It’s a great day when years of research comes out to the world! Great work from a great team! St. Jude Research stjude.org/media-resource…

Come join my lab as a sr. scientist focused on applied integrative biology to develop and implement novel technical approaches for assaying single cell dynamics, high throughput functional screening, and high parameter molecular phenotyping. tinyurl.com/3466kx8u #NowHiring

I’m hiring a sr. bioinformatics research scientist in integrative analysis to perform data analysis and visualization, statistical analysis, experimental design, database development, mathematical modeling, and novel method development. Join the team. tinyurl.com/39fz6cwy

The Foltz lab is growing! If you are interested in working on improving NK cell therapies for cancer, consider applying at: wustl.wd1.myworkdayjobs.com/en-US/External… or reaching out to us at jfoltzlab.org! WashU Medicine Department of Medicine WUSTL Immunology Siteman Cancer Center

Esther Obeng leads a research group focused on myelodysplastic syndromes (MDS) Emory School of Medicine. Journal of Experimental Medicine spoke with Esther about her career, how her patients inform her research, and more #WomenInSTEM rupress.org/jem/article/22…

🔬 Join us for a live webinar: “Cell Avidity Uncovers Novel KIR:HLA Binding — Predicting Patient Survival Post Stem Cell Transplant” with Dr. Peter Chockley 📅 November 19, 2025 | 4PM (EST) 🔗 Register now: lumicks.com/event/webinar/… #CellTherapy #NKcells #KIRHLA #StemCellTransplant